{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:20:36Z","timestamp":1792099236647,"version":"4.4.0"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["T32MH20031"],"award-info":[{"award-number":["T32MH20031"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute for Drug Abuse","doi-asserted-by":"crossref","award":["R01 DA033679"],"award-info":[{"award-number":["R01 DA033679"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute for Drug Abuse","doi-asserted-by":"crossref","award":["K24 DA017072"],"award-info":[{"award-number":["K24 DA017072"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The volatile opioid epidemic is associated with higher levels of opioid use disorder (OUD) and negative health outcomes in adolescents and young adults. Medications for opioid use disorder (MOUD) demonstrate the best evidence for treating OUD. Adherence to and retention in MOUD, defined as continuous engagement in treatment, among adolescents and young adults, however, is incompletely understood. We examined the state of the literature regarding the association of age with adherence to and retention in MOUD using methadone, buprenorphine, or naltrexone among persons aged 10\u201324 years, along with related facilitators and barriers. All studies of MOUD were searched for that examined adherence, retention, or related concepts as an outcome variable and included adolescents or young adults. Search criteria generated 10,229 records; after removing duplicates and screening titles and abstracts, 587 studies were identified for full-text review. Ultimately, 52 articles met inclusion criteria for abstraction and 17 were selected for qualitative coding and analysis. Younger age was consistently associated with shorter retention, although the overall quality of included studies was low. Several factors at the individual, interpersonal, and institutional levels, such as concurrent substance use, MOUD adherence, family conflict, and MOUD dosage and flexibility, appeared to have roles in MOUD retention among adolescents and young adults. Ways MOUD providers can tailor treatment to increase retention of adolescents and young adults are highlighted, as is the need for more research explaining MOUD adherence and retention disparities in this age group.<\/jats:p>","DOI":"10.1093\/epirev\/mxaa001","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T19:16:24Z","timestamp":1585595784000},"page":"41-56","source":"Crossref","is-referenced-by-count":55,"title":["Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults"],"prefix":"10.1093","volume":"42","author":[{"given":"Adam","family":"Viera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"Bromberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Whittaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan M","family":"Refsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Stanojlovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Nyhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L","family":"Altice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,2]]},"reference":[{"key":"2024012417092328600_ref1","doi-asserted-by":"crossref","DOI":"10.18356\/d29e3f27-en","volume-title":"World Drug Report: 2018","author":"United Nations Office on Drugs and Crime","year":"2018"},{"issue":"12","key":"2024012417092328600_ref2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","article-title":"The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016","volume":"5","author":"Degenhardt","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"2024012417092328600_ref3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cpr.2009.10.006","article-title":"A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction","volume":"30","author":"Veilleux","year":"2010","journal-title":"Clin Psychol Rev"},{"issue":"3","key":"2024012417092328600_ref4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2215-0366(15)00508-8","article-title":"The increasing global health priority of substance use in young people","volume":"3","author":"Degenhardt","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"2024012417092328600_ref5","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1176\/appi.ajp.160.6.1041","article-title":"Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability","volume":"160","author":"Chambers","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"2","key":"2024012417092328600_ref6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: review of the evidence and future directions","volume":"23","author":"Connery","year":"2015","journal-title":"Harv Rev Psychiatry"},{"key":"2024012417092328600_ref7","volume-title":"National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use","author":"American Society for Addiction Medicine"},{"issue":"9","key":"2024012417092328600_ref8","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1111\/j.1360-0443.2008.02249.x","article-title":"Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV\/AIDS","volume":"103","author":"Lawrinson","year":"2008","journal-title":"Addiction"},{"issue":"5","key":"2024012417092328600_ref9","first-page":"CD011117","article-title":"Opioid agonist treatment for pharmaceutical opioid dependent people","author":"Nielsen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"2024012417092328600_ref10","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.jaac.2011.07.010","article-title":"Predictors of abstinence: National Institute of drug abuse multisite buprenorphine\/naloxone treatment trial in opioid-dependent youth","volume":"50","author":"Subramaniam","year":"2011","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"2024012417092328600_ref11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1370\/afm.2098","article-title":"Mortality associated with time in and out of buprenorphine treatment in French office-based general practice: a 7-year cohort study","volume":"15","author":"Dupouy","year":"2017","journal-title":"Ann Fam Med"},{"key":"2024012417092328600_ref12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jsat.2016.12.005","article-title":"Mortality related to methadone maintenance treatment in Stockholm, Sweden, during 2006-2013","volume":"74","author":"Ledberg","year":"2017","journal-title":"J Subst Abuse Treat"},{"issue":"13","key":"2024012417092328600_ref13","first-page":"63","article-title":"The effect of methadone maintenance treatment (MMT) on the mental health of opium and heroin addicts","volume":"4","author":"Arefnasab","year":"2007","journal-title":"J Iran Psychol"},{"issue":"6","key":"2024012417092328600_ref14","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/add.12863","article-title":"Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10","volume":"110","author":"Evans","year":"2015","journal-title":"Addiction"},{"issue":"1","key":"2024012417092328600_ref15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.drugpo.2013.08.004","article-title":"What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries","volume":"25","author":"Degenhardt","year":"2014","journal-title":"Int J Drug Policy"},{"issue":"12","key":"2024012417092328600_ref16","doi-asserted-by":"crossref","first-page":"e1208","DOI":"10.1016\/S2214-109X(17)30373-X","article-title":"Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review","volume":"5","author":"Larney","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"2","key":"2024012417092328600_ref17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/00952990.2017.1399403","article-title":"Medication-assisted treatment for youth with opioid use disorder: current dilemmas and remaining questions","volume":"44","author":"Chang","year":"2018","journal-title":"Am J Drug Alcohol Abuse"},{"key":"2024012417092328600_ref18","volume-title":"Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence","author":"World Health Organization","year":"2009"},{"issue":"3","key":"2024012417092328600_ref19","doi-asserted-by":"crossref","first-page":"e20161893","DOI":"10.1542\/peds.2016-1893","article-title":"Medication-assisted treatment of adolescents with opioid use disorders","volume":"138","author":"American Academy of Pediatrics Committee on Substance Use and Prevention","year":"2016","journal-title":"Pediatrics"},{"issue":"11","key":"2024012417092328600_ref20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jamapediatrics.2018.2143","article-title":"Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder","volume":"172","author":"Hadland","year":"2018","journal-title":"JAMA Pediatr"},{"issue":"6","key":"2024012417092328600_ref21","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jadohealth.2016.12.023","article-title":"Medication-assisted treatment for adolescents in specialty treatment for opioid use disorder","volume":"60","author":"Feder","year":"2017","journal-title":"J Adolesc Health"},{"issue":"12","key":"2024012417092328600_ref22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/cbl.30178","article-title":"Maintenance buprenorphine for adults, but tapers for teens: why?","volume":"32","author":"Knopf","year":"2016","journal-title":"Brown University Child Adolesc Behav Lett"},{"key":"2024012417092328600_ref23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","article-title":"Long-term retention in office based opioid treatment with buprenorphine","volume":"74","author":"Weinstein","year":"2017","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"2024012417092328600_ref24","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/ajad.12414","article-title":"Predictors of early dropout in outpatient buprenorphine\/naloxone treatment","volume":"25","author":"Marcovitz","year":"2016","journal-title":"Am J Addict"},{"issue":"6","key":"2024012417092328600_ref25","first-page":"CD007210","article-title":"Maintenance treatments for opiate-dependent adolescents","author":"Minozzi","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2024012417092328600_ref26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0740-5472(02)00250-7","article-title":"Adolescent heroin use: a review of the descriptive and treatment literature","volume":"23","author":"Hopfer","year":"2002","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"2024012417092328600_ref27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: a systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"J Addict Dis"},{"issue":"8","key":"2024012417092328600_ref28","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.cpr.2013.07.007","article-title":"Drop-out from addiction treatment: a systematic review of risk factors","volume":"33","author":"Brorson","year":"2013","journal-title":"Clin Psychol Rev"},{"key":"2024012417092328600_ref29","volume-title":"Medication-assisted treatment adherence and retention among adolescents and young adults with opioid use disorders.","author":"Viera","year":"2018"},{"issue":"7","key":"2024012417092328600_ref30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1037\/0003-066X.32.7.513","article-title":"Toward an experimental ecology of human development","volume":"32","author":"Bronfenbrenner","year":"1977","journal-title":"Am Psychol"},{"issue":"4","key":"2024012417092328600_ref31","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2024012417092328600_ref32","volume-title":"How to GRADE the quality of the evidence","author":"Ryan","year":"2016"},{"issue":"7","key":"2024012417092328600_ref33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"6","key":"2024012417092328600_ref34","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1192\/pb.bp.111.035063","article-title":"Predictors for retention in treatment with a UK community-based naltrexone programme for opioid dependence","volume":"36","author":"Chaudhry","year":"2012","journal-title":"The Psychiatrist"},{"key":"2024012417092328600_ref35","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.drugalcdep.2016.12.009","article-title":"J-shaped relationship between supervised methadone consumption and retention in methadone maintenance treatment (MMT) in primary care: national cohort study","volume":"173","author":"Cousins","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"2024012417092328600_ref36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/0959523021000023180","article-title":"Characteristics, retention and readmissions of opioid-dependent clients treated with oral naltrexone","volume":"21","author":"Bartu","year":"2002","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"2024012417092328600_ref37","first-page":"130","article-title":"Does buprenorphine maintenance improve the quality of life of opioid users?","volume":"137","author":"Dhawan","year":"2013","journal-title":"Indian J Med Res"},{"issue":"1","key":"2024012417092328600_ref38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/08897077.2011.616816","article-title":"Opioid agonist maintenance for probationers: patient-level predictors of treatment retention, drug use, and crime","volume":"33","author":"Gryczynski","year":"2012","journal-title":"Subst Abus"},{"issue":"7","key":"2024012417092328600_ref39","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/ajad.12437","article-title":"Impact of early childhood trauma on retention and phase advancement in an outpatient buprenorphine treatment program","volume":"25","author":"Kumar","year":"2016","journal-title":"Am J Addict"},{"issue":"1","key":"2024012417092328600_ref40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3109\/10826084.2014.957769","article-title":"Psychological predictors of retention in a low-threshold methadone maintenance treatment for opioid addicts: a 1-year follow-up study","volume":"50","author":"Perreault","year":"2015","journal-title":"Subst Use Misuse"},{"key":"2024012417092328600_ref41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jsat.2017.06.005","article-title":"Association of methadone dose with substance use and treatment retention in pregnant and postpartum women with opioid use disorder","volume":"80","author":"Wilder","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"2024012417092328600_ref42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1477-7517-7-29","article-title":"Opioid substitution therapy in Manipur and Nagaland, north-East India: operational research in action","volume":"7","author":"Armstrong","year":"2010","journal-title":"Harm Reduct J"},{"issue":"10","key":"2024012417092328600_ref43","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1360-0443.1997.tb02854.x","article-title":"Predictors of patient retention in a newly established methadone maintenance treatment programme","volume":"92","author":"del Rio","year":"1997","journal-title":"Addiction"},{"key":"2024012417092328600_ref44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.drugpo.2017.05.014","article-title":"Retention in medication-assisted treatment programs in Ukraine-identifying factors contributing to a continuing HIV epidemic","volume":"48","author":"Dumchev","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"4","key":"2024012417092328600_ref45","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jsat.2009.05.003","article-title":"Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year","volume":"37","author":"Soeffing","year":"2009","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"2024012417092328600_ref46","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/02791072.2014.904061","article-title":"Buprenorphine prescription compliance: an original observational and longitudinal study","volume":"46","author":"Guillou Landreat","year":"2014","journal-title":"J Psychoactive Drugs"},{"issue":"3","key":"2024012417092328600_ref47","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1360-0443.1971.tb02386.x","article-title":"Patient characteristics associated with retention in a methadone maintenance program","volume":"66","author":"Babst","year":"1971","journal-title":"Br J Addict Alcohol Other Drugs"},{"issue":"1\u20132","key":"2024012417092328600_ref48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.drugalcdep.2012.12.008","article-title":"Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes","volume":"131","author":"Haddad","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"2024012417092328600_ref49","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0376-8716(98)00091-X","article-title":"Retention in treatment of heroin users in Italy: the role of treatment type and of methadone maintenance dosage","volume":"52","author":"D'Ippoliti","year":"1998","journal-title":"Drug Alcohol Depend"},{"key":"2024012417092328600_ref50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2016.04.002","article-title":"One-year follow-up of heroin-dependent adolescents treated with buprenorfine\/naloxone for the first time in a substance treatment unit","volume":"67","author":"Mutlu","year":"2016","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"2024012417092328600_ref51","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/08897077.2016.1143435","article-title":"Relapse prevention medications in community treatment for young adults with opioid addiction","volume":"37","author":"Vo","year":"2016","journal-title":"Subst Abus"},{"issue":"3","key":"2024012417092328600_ref52","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jsat.2014.04.006","article-title":"Emerging adult age status predicts poor buprenorphine treatment retention","volume":"47","author":"Schuman-Olivier","year":"2014","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"2024012417092328600_ref53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1300\/J069v25n03_03","article-title":"Adolescent and young adult heroin patients: drug use and success in methadone maintenance treatment","volume":"25","author":"Kellogg","year":"2006","journal-title":"J Addict Dis"},{"issue":"3","key":"2024012417092328600_ref54","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/ADM.0000000000000035","article-title":"A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine\/naloxone clinic","volume":"8","author":"Matson","year":"2014","journal-title":"J Addict Med"},{"issue":"9","key":"2024012417092328600_ref55","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.addbeh.2012.04.011","article-title":"Predictors of attrition with buprenorphine\/naloxone treatment in opioid dependent youth","volume":"37","author":"Warden","year":"2012","journal-title":"Addict Behav"},{"issue":"2","key":"2024012417092328600_ref56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/09595230500537209","article-title":"Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling","volume":"25","author":"Korn\u00f8r","year":"2006","journal-title":"Drug Alcohol Rev"},{"key":"2024012417092328600_ref57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2017.06.004","article-title":"A naturalistic study of predictors of retention in treatment among emerging adults entering first buprenorphine maintenance treatment for opioid use disorders","volume":"80","author":"Dayal","year":"2017","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"2024012417092328600_ref58","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12887-018-1137-4","article-title":"Opioid substitution treatment and heroin dependent adolescents: reductions in heroin use and treatment retention over twelve months","volume":"18","author":"Smyth","year":"2018","journal-title":"BMC Pediatr"},{"issue":"ebs, 7513587","key":"2024012417092328600_ref59","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drugalcdep.2015.09.020","article-title":"Memantine improves buprenorphine\/naloxone treatment for opioid dependent young adults","volume":"156","author":"Gonzalez","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"2024012417092328600_ref60","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/09595230500537670","article-title":"Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: a file review","volume":"25","author":"Bell","year":"2006","journal-title":"Drug Alcohol Rev"},{"issue":"5\u20136 Suppl 1","key":"2024012417092328600_ref61","first-page":"29","article-title":"Use of methadone therapy at the Institute for Alcoholism and Drug Addiction in the Canton of Sarajevo","volume":"57","author":"Haseci\u0107","year":"2003","journal-title":"Med Arh"},{"issue":"2","key":"2024012417092328600_ref62","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/BF03405776","article-title":"Client retention in the British Columbia methadone program, 1996-1999","volume":"95","author":"Anderson","year":"2004","journal-title":"Can J Public Health"},{"issue":"8","key":"2024012417092328600_ref63","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1360-0443.2009.02633.x","article-title":"Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention","volume":"104","author":"Burns","year":"2009","journal-title":"Addiction"},{"issue":"4","key":"2024012417092328600_ref64","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/add.12834","article-title":"A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia","volume":"110","author":"Burns","year":"2015","journal-title":"Addiction"},{"issue":"2","key":"2024012417092328600_ref65","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/02791072.1993.10472244","article-title":"Strategies for increasing retention in methadone programs","volume":"25","author":"Condelli","year":"1993","journal-title":"J Psychoactive Drugs"},{"key":"2024012417092328600_ref66","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.addbeh.2017.05.010","article-title":"Predictors of buprenorphine treatment success of opioid dependence in two Baltimore City grassroots recovery programs","volume":"73","author":"Damian","year":"2017","journal-title":"Addict Behav"},{"issue":"1","key":"2024012417092328600_ref67","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF02287327","article-title":"Retention in publicly funded methadone maintenance treatment in two Western States","volume":"32","author":"Deck","year":"2005","journal-title":"J Behav Health Serv Res"},{"issue":"5","key":"2024012417092328600_ref68","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jsat.2012.11.006","article-title":"Effectiveness of drug tests in outpatients starting opioid substitution therapy","volume":"44","author":"Dupouy","year":"2013","journal-title":"J Subst Abuse Treat"},{"issue":"9","key":"2024012417092328600_ref69","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/j.1360-0443.2010.03015.x","article-title":"Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility","volume":"105","author":"Fishman","year":"2010","journal-title":"Addiction"},{"issue":"2","key":"2024012417092328600_ref70","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/002204269702700202","article-title":"Predictors of treatment retention in enhanced and standard methadone maintenance treatment for HIV risk reduction","volume":"27","author":"Grella","year":"1997","journal-title":"J Drug Issues"},{"issue":"1","key":"2024012417092328600_ref71","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"issue":"1","key":"2024012417092328600_ref72","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3109\/00952997509002724","article-title":"Retention in treatment of drug users: 1971\u20131972 DARP admissions","volume":"2","author":"Joe","year":"1975","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"5","key":"2024012417092328600_ref73","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/cid\/ciu382","article-title":"Methadone treatment for HIV prevention-feasibility, retention, and predictors of attrition in Dar Es Salaam, Tanzania: a retrospective cohort study","volume":"59","author":"Lambdin","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2024012417092328600_ref74","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/ajad.12533","article-title":"Hospitalized opioid-dependent patients: exploring predictors of buprenorphine treatment entry and retention after discharge","volume":"26","author":"Lee","year":"2017","journal-title":"Am J Addict"},{"issue":"1","key":"2024012417092328600_ref75","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/pds.4647","article-title":"Adherence trajectories of buprenorphine therapy among pregnant women in a large state Medicaid program in the United States","volume":"28","author":"Lo-Ciganic","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"2024012417092328600_ref76","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jadohealth.2012.10.045","article-title":"Opiate abstinence among adolescents engaged in an outpatient buprenorphine clinic for the treatment of opiate dependence","volume":"52","author":"Matson","year":"2013","journal-title":"J Adolesc Health"},{"issue":"8","key":"2024012417092328600_ref77","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/ajad.12641","article-title":"Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders","volume":"26","author":"Romero-Gonzalez","year":"2017","journal-title":"Am J Addict"},{"key":"2024012417092328600_ref78","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12954-015-0062-1","article-title":"Cross-sectional assessments of participants\u2019 characteristics and loss to follow-up in the first opioid substitution therapy pilot program in Kabul","volume":"12","author":"Ruisenor-Escudero","year":"2015","journal-title":"Harm Reduct J"},{"key":"2024012417092328600_ref79","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","article-title":"Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees","volume":"95","author":"Samples","year":"2018","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"2024012417092328600_ref80","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1046\/j.1360-0443.1996.918119711.x","article-title":"Pre-treatment characteristics, program philosophy and level of ancillary services as predictors of methadone maintenance treatment outcome","volume":"91","author":"Saxon","year":"1996","journal-title":"Addiction"},{"issue":"10","key":"2024012417092328600_ref81","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.addbeh.2007.01.010","article-title":"Retention and illicit drug use among methadone patients in Israel: a gender comparison","volume":"32","author":"Schiff","year":"2007","journal-title":"Addict Behav"},{"issue":"1","key":"2024012417092328600_ref82","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jsat.2011.07.007","article-title":"Outcome of heroin-dependent adolescents presenting for opiate substitution treatment","volume":"42","author":"Smyth","year":"2012","journal-title":"J Subst Abuse Treat"},{"key":"2024012417092328600_ref83","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jsat.2017.08.007","article-title":"Home-based delivery of XR-NTX in youth with opioid addiction","volume":"85","author":"Vo","year":"2018","journal-title":"J Subst Abuse Treat"}],"container-title":["Epidemiologic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/epirev\/advance-article-pdf\/doi\/10.1093\/epirev\/mxaa001\/34275043\/mxaa001.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/epirev\/article-pdf\/42\/1\/41\/56346078\/mxaa001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/epirev\/article-pdf\/42\/1\/41\/56346078\/mxaa001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T17:10:11Z","timestamp":1706116211000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/epirev\/article\/42\/1\/41\/5814898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,4,2]]},"published-print":{"date-parts":[[2020,1,31]]}},"URL":"https:\/\/doi.org\/10.1093\/epirev\/mxaa001","relation":{},"ISSN":["1478-6729"],"issn-type":[{"value":"1478-6729","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020]]},"published":{"date-parts":[[2020]]}}}